Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations and further to its earlier intimation dated April 16, 2025, in respect of a patent infringement dispute with Astellas Pharma, Inc., Astellas Ireland Co., and Astellas Pharma Global Development, Inc. (collectively ‘Astellas’) in relation to its product ‘Mirabegron’, Lupin has informed that the Company and its wholly owned subsidiary Lupin Pharmaceuticals, Inc., USA, have entered into a Settlement and License Agreement (‘Agreement’) with Astellas. Under the terms of the Agreement, Lupin will pay Astellas (1) USD 90 million, which includes a Prepaid Option Payment of USD 75 million, and (2) a Prepaid Per Unit License Fee for each unit of Lupin Product sold from the date of the settlement through September 2027. The settlement terms are confidential. This settlement resolves Lupin’s pending litigation with Astellas and allows Lupin to continue to sell its Mirabegron product.

The above information is a part of company’s filings submitted to BSE.